Skip to search formSkip to main contentSkip to account menu

NVP BEZ235

Known as: NVP-BEZ235, NVPBEZ235 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

dactolisib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapy
Purpose NVP-BEZ235 is a recently developed dual inhibitor of PI3K and mTOR and shows good inhibitory effects on several types of… 
2015
2015
Dual inhibition of phosphatidylinositol 3-kinase/mammalian target of rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphoma
NHL subtypes are classified based on clinical and histologic characteristics, as well as lymphocyte developmental stage. NHL sub… 
2015
2015
Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor…
2014
2014
The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances the Antitumoral Activity of Gemcitabine in Human Pancreatic Cancer Cell Lines
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most common malignant tumors still associated with poor… 
2013
2013
Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down‐regulation of Mcl‐1 in mantle cell lymphoma
Mantle cell lymphoma (MCL) is an aggressive form of Non‐Hodgkin‐lymphoma (NHL) with an ongoing need for novel treatments. Apart… 
2012
2012
RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor Growth
The mammalian target of rapamycin (mTOR) is regulated by oncogenic growth factor signals and plays a pivotal role in controlling… 
2012
2012
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy
Objectives: Mantle cell lymphoma (MCL) is a distinct subtype of B-cell lymphoma; the complete response rate for standard… 
2012
2012
The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
2010
2010
High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy.
Highly Cited
2009
Highly Cited
2009
Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase.
Phosphatidylinositol 3-kinase (PI3K) has been implicated in a variety of diseases including cancer. A number of PI3K inhibitors… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)